Civitico G, Shaw T, Locarnini S
Victorian Infectious Diseases Reference Laboratory, Fairfield Hospital, Australia.
Antimicrob Agents Chemother. 1996 May;40(5):1180-5. doi: 10.1128/AAC.40.5.1180.
Safe and effective treatments for chronic hepatitis B virus (HBV) infection have yet to be developed. Both ganciclovir (9-[1,3-dihydroxy-2-propoxymethyl]guanine) and foscarnet (trisodium phosphonoformate hexahydrate) are potent inhibitors of hepadnavirus replication when used individually in vitro and in vivo. However, the clinical usefulness of each drug is reduced by dose-limiting toxicity, especially during long-term monotherapy. Here we demonstrate additive inhibition of duck HBV DNA replication in cultures of primary duck hepatocytes congenitally infected with duck HBV by combinations of ganciclovir and foscarnet at low, clinically achievable concentrations. These results suggest that the effects of ganciclovir and foscarnet against HBV may be additive in vivo.
针对慢性乙型肝炎病毒（HBV）感染的安全有效的治疗方法尚未研发出来。更昔洛韦（9-[1,3-二羟基-2-丙氧甲基]鸟嘌呤）和膦甲酸钠（六水合膦甲酸钠三钠）在体外和体内单独使用时都是乙肝病毒复制的有效抑制剂。然而，每种药物的临床效用都因剂量限制性毒性而降低，尤其是在长期单一疗法期间。在此，我们证明了在先天性感染鸭乙肝病毒的原代鸭肝细胞培养物中，更昔洛韦和膦甲酸钠以低的、临床可达到的浓度联合使用时，对鸭乙肝病毒DNA复制具有相加抑制作用。这些结果表明，更昔洛韦和膦甲酸钠对乙肝病毒的作用在体内可能是相加的。
